
Sabine Eichinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7724532/publications.pdf Version: 2024-02-01



SARINE FICHINCER

#	Article	IF	CITATIONS
1	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 2021, 384, 2092-2101.	27.0	1,765
2	The Risk of Recurrent Venous Thromboembolism in Men and Women. New England Journal of Medicine, 2004, 350, 2558-2563.	27.0	432
3	Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism. Circulation, 2010, 121, 1630-1636.	1.6	425
4	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis, 2012, 10, 1019-1025.	3.8	353
5	Overweight, Obesity, and the Risk of Recurrent Venous Thromboembolism. Archives of Internal Medicine, 2008, 168, 1678.	3.8	269
6	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 32-67.	2.1	243
7	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ: British Medical Journal, 2019, 366, 14363.	2.3	177
8	Clinical Studies and Thrombin Generation in Patients Homozygous or Heterozygous for the G20210A Mutation in the Prothrombin Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1287-1291.	2.4	147
9	Prediction of Recurrent Venous Thromboembolism by Endogenous Thrombin Potential and D-Dimer. Clinical Chemistry, 2008, 54, 2042-2048.	3.2	122
10	High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism. Circulation, 2007, 115, 1609-1614.	1.6	102
11	<scp>d</scp> â€Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model. Journal of the American Heart Association, 2014, 3, e000467.	3.7	75
12	Cancer associated thrombosis: risk factors and outcomes. Thrombosis Research, 2016, 140, S12-S17.	1.7	64
13	The longâ€ŧerm recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study. Journal of Thrombosis and Haemostasis, 2016, 14, 2402-2409.	3.8	63
14	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2021, 174, 1420-1429.	3.9	60
15	Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusaiâ€ <scp>VTE</scp> study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1581-1589.	2.3	55
16	Association of cardiometabolic microRNAs with COVID-19 severity and mortality. Cardiovascular Research, 2022, 118, 461-474.	3.8	51
17	High proportion of patients with bleeding of unknown cause in persons with a mildâ€ŧoâ€moderate bleeding tendency: Results from the Vienna Bleeding Biobank (VIBB). Haemophilia, 2018, 24, 405-413.	2.1	49
18	Age at First Venous Thromboembolism and Risk of Recurrence. Medicine (United States), 2009, 88, 366-370	1.0	45

_

#	Article	IF	CITATIONS
19	6 versus 30Âmonths anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Annals of Hematology, 2009, 88, 485-490.	1.8	39
20	Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. Journal of Thrombosis and Haemostasis, 2016, 14, 273-281.	3.8	37
21	Hematocrit and the Risk of Recurrent Venous Thrombosis: A Prospective Cohort Study. PLoS ONE, 2012, 7, e38705.	2.5	33
22	D-Dimer Testing in Pregnancy. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 327-329.	0.3	31
23	D-Dimer Testing in Pregnancy. Seminars in Vascular Medicine, 2005, 05, 375-378.	2.1	30
24	Extracellular Vesicles and Citrullinated Histone H3 in Coronavirus Disease 2019 Patients. Thrombosis and Haemostasis, 2022, 122, 113-122.	3.4	23
25	Homocysteine, Vitamin B6 and the Risk of Recurrent Venous Thromboembolism. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 342-344.	0.3	21
26	Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. European Journal of Clinical Investigation, 2009, 39, 707-713.	3.4	19
27	Longâ€ŧerm risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and metaâ€∎nalysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2801-2813.	3.8	19
28	Are B vitamins a risk factor for venous thromboembolism? Yes. Journal of Thrombosis and Haemostasis, 2006, 4, 307-308.	3.8	17
29	The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients Thrombosis and Haemostasis, 2010, 104, 92-99.	3.4	17
30	D-Dimer for Long-Term Risk Prediction in Patients After Acute Coronary Syndrome. Circulation, 2018, 138, 724-726.	1.6	15
31	Factor XI and recurrent venous thrombosis: an observational cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 782-786.	3.8	15
32	Duration of anticoagulation after initial idiopathic venous thrombosis – the swinging pendulum: Risk assessment to predict recurrence. Journal of Thrombosis and Haemostasis, 2009, 7, 291-295.	3.8	14
33	Reversing vitamin K antagonists: making the old new again. Hematology American Society of Hematology Education Program, 2016, 2016, 605-611.	2.5	14
34	Risk of venous thromboembolism during rehabilitation of patients with spinal cord injury. PLoS ONE, 2018, 13, e0193735.	2.5	14
35	Natural antibodies to oxidationâ€specific epitopes: innate immune response and venous thromboembolic disease. Journal of Thrombosis and Haemostasis, 2018, 16, 31-35.	3.8	10
36	Prediction of recurrent venous thromboembolism by measuring ProC Global. Thrombosis and Haemostasis, 2007, 98, 1232-1236.	3.4	10

#	Article	IF	CITATIONS
37	Diagnostic issues of VTE in pregnancy. Thrombosis Research, 2009, 123, S38-S40.	1.7	9
38	Prevention of deep vein thrombosis in orthopedic surgery. European Journal of Medical Research, 2004, 9, 112-8.	2.2	9
39	Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2020, 107, 415-422.	4.7	8
40	How I manage cyclic thrombocytopenia. Blood, 2021, 137, 178-184.	1.4	8
41	Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism. Inflammatory Bowel Diseases, 2021, 27, 1773-1783.	1.9	8
42	Clinical and laboratory characteristics of cyclic thrombocytopenia: an observational study. Haematologica, 2020, 105, e198-e201.	3.5	8
43	Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1368-1374.	3.8	6
44	Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, 016950.	1.9	6
45	Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial. Thrombosis Research, 2020, 195, 209-214.	1.7	6
46	Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients?. Case Reports in Immunology, 2021, 2021, 1-5.	0.4	6
47	A case of COVID-19 vaccination-associated forme fruste purpura fulminans. British Journal of Dermatology, 2022, 186, e1-e1.	1.5	6
48	Prevention of Venous Thrombosis in Cancer Patients: A randomized, Double-Blind Study Comparing Two Different Dosages of Low-Molecular Weight Heparin Blood, 2008, 112, 1977-1977.	1.4	6
49	Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study. Frontiers in Cardiovascular Medicine, 2021, 8, 749342.	2.4	5
50	Risk Assessment Model to Predict Recurrence in Patients with Unprovoked Deep Vein Thrombosis or Pulmonary Embolism Blood, 2009, 114, 452-452.	1.4	5
51	Effects of clopidogrel with or without aspirin on the generation of extracellular vesicles in the microcirculation and in venous blood: A randomized placebo controlled trial. Thrombosis Research, 2018, 167, 149-155.	1.7	4
52	Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 49, 505-510.	2.1	4
53	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. Blood, 2018, 132, 2527-2527.	1.4	4
54	Endogenous Thrombin Potential (ETP) for Assessing the Risk of Recurrent Venous Thromboembolism Blood, 2005, 106, 1622-1622.	1.4	4

#	Article	IF	CITATIONS
55	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins Blood, 2006, 108, 271-271.	1.4	4
56	Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. the Warfasa STUDY. Blood, 2011, 118, 543-543.	1.4	4
57	Homozygosity in the Single Nucleotide Polymorphism Ser128Arg in the E-Selectin Gene Is Associated with Recurrent Venous Thromboembolism Blood, 2006, 108, 4086-4086.	1.4	4
58	Effects of Recombinant Factor VIIa (NovoSeven®) on Restoring Thrombin Generation in Patients with Hemophilia A and Antibodies to Factor VIII Blood, 2007, 110, 1161-1161.	1.4	4
59	Consequences of thrombophilia screening for life quality in women before prescription of oral contraceptives and family members of VTE patients. Hamostaseologie, 2009, 29, 110-1.	1.9	4
60	MicroRNA Signatures in Plasma of Patients With Venous Thrombosis: A Preliminary Report. American Journal of the Medical Sciences, 2021, 361, 509-516.	1.1	3
61	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. HemaSphere, 2021, 5, e643.	2.7	3
62	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood, 2011, 118, 544-544.	1.4	3
63	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy. Pharmaceutics, 2022, 14, 662.	4.5	3
64	Treatment of venous thromboembolism. Wiener Medizinische Wochenschrift, 2005, 155, 7-10.	1.1	2
65	Medical Therapy in Venous Thromboembolism. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 186-190.	2.1	2
66	Oral anticoagulation and vitamin K deficiency. Hamostaseologie, 2014, 34, 237-238.	1.9	2
67	D-dimer levels over time after anticoagulation and the association with recurrent venous thromboembolism. Thrombosis Research, 2021, 197, 160-164.	1.7	2
68	Hypofibrinolysis and the Risk of Recurrent Venous Thromboembolism: A Prospective Cohort Study,. Blood, 2011, 118, 3331-3331.	1.4	2
69	Recurrent Venous Thromboembolism during Anticoagulation: An Investigator-Initiated Post-Hoc Analysis of the Hokusai-VTE Trial. Blood, 2018, 132, 2539-2539.	1.4	2
70	Differential Effects of Clopidogrel With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2021, 109, 1546-1554.	4.7	1
71	Sex, age and venous thrombosis—Are men and women indeed from different planets?. European Journal of Internal Medicine, 2021, 84, 16-17.	2.2	1
72	D-Dimer Levels Over Time and The Risk Of Recurrent Venous Thromboembolism: An Update Of The Vienna Prediction Model. Blood, 2013, 122, 462-462.	1.4	1

#	Article	IF	CITATIONS
73	Anticoagulation after venous thromboembolism. Hamostaseologie, 2013, 33, 211-217.	1.9	1
74	Characterization of the Procoagulant Activity of Two Different Microparticle Species Blood, 2010, 116, 1143-1143.	1.4	1
75	Thrombin generation and venous thromboembolism. Hamostaseologie, 2008, 28, 37-9.	1.9	1
76	Direkte orale Antikoagulantien: Welche Patienten eignen sich zur Behandlung mit diesen Substanzen?. Wiener Klinische Wochenschrift Education, 2015, 10, 1-13.	0.0	0
77	American Society of Hematology 2020 Podcast Collection: Immune Thrombocytopenia. Advances in Therapy, 2021, 38, 20-25.	2.9	Ο
78	Microparticles Are a Major Determinant of Thrombin Generation Measured by Technothrombin®TGA Blood, 2006, 108, 1462-1462.	1.4	0
79	Hematocrit and the Risk of Recurrent Venous Thrombosis: a Prospective Cohort Study. Blood, 2010, 116, 807-807.	1.4	Ο
80	Duration of anticoagulation after venous thrombosis. Vasa - European Journal of Vascular Medicine, 2012, 41, 11-17.	1.4	0
81	The Risk Of Recurrence In Women With Venous Thromboembolism While Using Estrogens: A Prospective Observational Cohort Study. Blood, 2013, 122, 1123-1123.	1.4	Ο
82	Naturally Occurring Autoantibodies to Oxidation-Specific Epitopes in Patients with Venous Thromboembolism. Blood, 2014, 124, 2861-2861.	1.4	0
83	Risk of Cancer after Long-Term Anticoagulation in Patients with Unprovoked Venous Thromboembolism. Blood, 2015, 126, 3545-3545.	1.4	0
84	the Long-Term Recurrence Risk of Patients with Unprovoked Venous Thromboembolism: An Observational Cohort Study. Blood, 2016, 128, 273-273.	1.4	0
85	Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Colorectal Cancer Patients: A Pilot Study. Blood, 2016, 128, 1425-1425.	1.4	Ο
86	Risk and Determinants of Provoked Recurrent Venous Thromboembolism: A Prospective Cohort Study. , 2019, 39, .		0
87	Identification of Patients with Unprovoked Venous Thromboembolism and a Low Risk of Recurrence Estimated By the Vienna Prediction Model: A Prospective Cohort Management Study. Blood, 2021, 138, 775-775	1.4	0